Dermatology · PANCE / PANRE

Erythema Multiforme

Acute self-limited immune-mediated mucocutaneous reaction with target lesions; most often triggered by HSV.

Also known as: erythema multiforme, EM, EM minor, EM major, target lesions

Overview

An acute, self-limited, immune-mediated mucocutaneous reaction characterized by typical 'target' (iris) lesions on extensor extremities and palms/soles. EM minor lacks significant mucosal involvement; EM major involves ≥1 mucous membrane.

Epidemiology

Peak ages 20-40; rare in children <5 and adults >50. Slight male predominance. Recurrent EM affects ~25% of patients, usually HSV-driven.

Try two board-style Erythema Multiforme questions

Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.

Question 1DermatologyMedium
A 28-year-old woman develops symmetric, targetoid skin lesions with three concentric color zones on her palms and the extensor surfaces of her arms and legs, along with painful erosions of the oral mucosa. Ten days earlier she had a recurrent cold sore on her lip from herpes simplex virus type 1. Which of the following is the most likely diagnosis?
  • AFixed drug eruption
  • BBullous impetigo
  • CUrticaria with angioedema
  • DErythema multiforme major
Reveal answer & full explanation
Correct answer: D — Erythema multiforme major
  • AFixed drug eruption
  • BBullous impetigo
  • CUrticaria with angioedema
  • DErythema multiforme major

Why Erythema multiforme major is correct

  • Classic three-zone target lesions on acral and extensor surfaces are the hallmark of erythema multiforme
  • Herpes simplex virus is the most common trigger, accounting for the majority of cases and typically preceding the eruption by 1-2 weeks
  • The designation "major" reflects significant mucosal (here, oral) involvement, distinguishing it from EM minor, which spares mucosa
  • HSV-associated EM is managed with antiviral therapy, and recurrent disease warrants suppressive acyclovir

Why the others are wrong

  • Fixed drug eruption — produces one or a few round, dusky plaques that recur at the SAME site with re-exposure to a culprit drug, not symmetric acral targets after HSV (confused-with a dusky single lesion)
  • Bullous impetigo — a staphylococcal infection with flaccid bullae and honey-colored crust, lacking target morphology or mucosal erosions (buzzword-matching skin blistering)
  • Urticaria with angioedema — transient migratory wheals that resolve within 24 hours without fixed targets or mucosal erosion (anchoring on an acute rash)
Question 2DermatologyMedium
A 28-year-old man presents with a 3-day history of a non-painful rash. Ten days earlier he had a cold sore on his lip that has since crusted over. Examination shows symmetric, raised lesions on the dorsal hands, forearms, palms, and soles; each lesion has three concentric zones — a dusky central area, a pale edematous ring, and an outer red halo. There is a single small erosion on the buccal mucosa. He takes no medications. A diagnosis of erythema multiforme is made. Which of the following best explains the findings?
  • AIgE-mediated mast cell degranulation with transient dermal vascular leak
  • BCD8+ T-cell–mediated keratinocyte apoptosis at viral antigen deposits
  • CFas/Fas-ligand–mediated keratinocyte apoptosis from a reactive drug metabolite
  • DIgG autoantibody attack on desmoglein-3 disrupting keratinocyte adhesion
Reveal answer & full explanation
Correct answer: B — CD8+ T-cell–mediated keratinocyte apoptosis at viral antigen deposits
  • AIgE-mediated mast cell degranulation with transient dermal vascular leak
  • BCD8+ T-cell–mediated keratinocyte apoptosis at viral antigen deposits
  • CFas/Fas-ligand–mediated keratinocyte apoptosis from a reactive drug metabolite
  • DIgG autoantibody attack on desmoglein-3 disrupting keratinocyte adhesion

Why CD8+ T-cell–mediated keratinocyte apoptosis at viral antigen deposits is correct

  • Erythema multiforme is a delayed-type (type IV) hypersensitivity reaction; here the preceding herpes labialis identifies HSV as the trigger (HSV accounts for >=50% of cases and >70% of recurrent EM).
  • HSV DNA fragments are carried to keratinocytes by Langerhans cell precursors, provoking a CD4+ Th1 / IFN-gamma response and CD8+ T-cell–mediated apoptosis of HSV-antigen–bearing keratinocytes — producing the classic acral, three-zone target lesions seen here.

Why the others are wrong

  • Fas/Fas-ligand–mediated keratinocyte apoptosis from a reactive drug metabolite — this is the mechanism of Stevens-Johnson syndrome / TEN, which is drug-induced with diffuse flat atypical targets and truncal predominance; this patient is on no drugs and has true three-zone acral targets following an HSV outbreak.
  • IgE-mediated mast cell degranulation with transient dermal vascular leak — this is type I hypersensitivity (urticaria/anaphylaxis); it produces transient wheals lasting <24 h, not fixed three-zone target lesions with epidermal injury.
  • IgG autoantibody attack on desmoglein-3 disrupting keratinocyte adhesion — this is the mechanism of pemphigus vulgaris, an antibody-mediated acantholytic disease causing flaccid bullae and oral erosions with a positive Nikolsky sign, not target lesions.
🔒 Free preview limit reached

Keep reading — start your free trial

You've read your 2 free diagnosis previews. Create your free account to unlock the full Erythema Multiforme outline — plus all 514 diagnoses, 6,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.

Free to start · No credit card · Cancel anytime

Risk factors

  • Herpes simplex virus (HSV-1 > HSV-2) — implicated in ≥50% of cases and >70% of recurrent EM
  • Mycoplasma pneumoniae — especially in children and adolescents
  • Other infections: EBV, CMV, hepatitis viruses, parvovirus B19, COVID-19, fungi, parasites
  • Drugs: rare cause of true EM (more often cause SJS/TEN) — NSAIDs, sulfonamides, antiepileptics
  • Autoimmune disease: SLE, IBD, sarcoidosis (rare)
  • Vaccines (rare)

Pathophysiology

Delayed-type hypersensitivity (type IV) reaction with CD8+ T-cell mediated keratinocyte apoptosis at sites of HSV antigen deposition. HSV DNA fragments (especially the pol gene) are transported to keratinocytes by CD34+ Langerhans cell precursors, triggering CD4+ Th1 response → IFN-γ → keratinocyte injury. EM is now considered immunopathogenically distinct from SJS/TEN (which is drug-induced, more diffuse Fas/FasL-mediated apoptosis).

Clinical presentation

Symptoms

  • Prodrome may be absent (EM minor) or mild (low-grade fever, malaise)
  • Burning or pruritus of lesions
  • Oral pain, dysphagia (EM major)
  • Recurrent HSV often precedes outbreak by 7-10 days

Signs / physical exam

  • Typical target ('iris') lesion: 3 concentric zones — central dusky/dark purple or vesicular zone, middle pale edematous ring, outer erythematous halo
  • Atypical target: 2 zones (raised palpable lesion with single ring)
  • Distribution: acral and symmetric — extensor surfaces of hands, forearms, feet, knees, elbows, face; palms and soles characteristically involved
  • Koebner phenomenon at sites of trauma
  • EM minor: skin only or single mucosal site (oral)
  • EM major: ≥1 mucous membrane (oral, ocular, genital) with erosions/crusts; lips classically with hemorrhagic crusts
  • Lesions appear over 3-5 days, persist for 1-2 weeks, resolve over 2-4 weeks; recurrent episodes lasting weeks

Classic findings

Acral and symmetric distribution of true 3-zone target lesions involving palms and soles, often preceded by HSV outbreak.

Differential diagnosis

  • Stevens-Johnson syndrome / TEN — Drug-induced, prodrome of fever/malaise, widespread atypical FLAT targets, mucosal involvement severe, BSA detachment <10% (SJS) to >30% (TEN); NOT acral predominance
  • Urticaria multiforme — Polycyclic urticarial plaques with central clearing in children — lesions transient (<24 h), no true epidermal detachment; resolves quickly with antihistamines
  • Fixed drug eruption — Single or few round dusky plaques recurring in same location after drug exposure
  • Bullous pemphigoid — Tense bullae on urticarial base in elderly; DIF positive
  • Pemphigus vulgaris — Painful oral erosions, flaccid bullae, positive Nikolsky; DIF positive
  • Sweet syndrome — Painful red plaques with neutrophilic infiltrate, fever, leukocytosis; associated with malignancy or infection
  • Vasculitis (small vessel) — Palpable purpura on lower extremities; biopsy
  • Rowell syndrome (SLE) — EM-like lesions + SLE features + anti-La (SSB) positivity

Diagnostic workup

Diagnostic criteria

Clinical: typical target lesions in acral distribution ± mucosal involvement; biopsy if atypical.

Labs

  • Clinical diagnosis — characteristic morphology and distribution
  • Skin biopsy if atypical: interface dermatitis with apoptotic keratinocytes, lymphocytic infiltrate (less full-thickness necrosis than SJS/TEN)
  • HSV PCR or culture of any vesicles; serology
  • Mycoplasma pneumoniae PCR, IgM, cold agglutinins; chest X-ray if respiratory symptoms
  • CBC, CMP, ESR to exclude systemic illness
  • Review medications (consider SJS/TEN if recent new drug)

Imaging

  • Chest X-ray if Mycoplasma suspected

Diagnostic algorithm

FeatureEM MinorEM MajorSJS / TEN
TriggerHSV most commonHSV, MycoplasmaDrugs (>80%)
LesionsTypical 3-zone targetsTypical targets + bullaeAtypical flat targets, dusky macules
DistributionAcral (extensors, palms/soles)Acral with some truncalTruncal predominant
MucosaAbsent or single site≥1 mucosa≥2 mucosae, severe
DetachmentNoneMinimal (<10% if any)<10% SJS / 10-30% overlap / >30% TEN
TreatmentSymptomatic, treat triggerTreat trigger, ± systemic steroidsStop drug, supportive ICU/burn unit care
Distinguishing erythema multiforme from SJS/TEN.

Treatment

First-line

  • Identify and treat trigger: oral acyclovir 400 mg 5x/day or valacyclovir 1 g TID × 7 days if active HSV; azithromycin 500 mg day 1 then 250 mg × 4 days for Mycoplasma
  • Symptomatic care: oral antihistamines for pruritus, topical corticosteroids for skin lesions, magic mouthwash (viscous lidocaine, diphenhydramine, antacid) for oral erosions
  • Hydration, soft diet, attention to nutrition
  • Discontinue any potentially offending drugs (if drug-induced EM rather than infectious)
  • EM is self-limited — most cases resolve in 2-4 weeks without treatment

Recurrent EM (HSV-driven)

  • Chronic suppressive antiviral: acyclovir 400 mg BID, valacyclovir 500-1000 mg daily, or famciclovir 250 mg BID — for at least 6-12 months
  • Effective in 80-90% of HSV-associated recurrent EM
  • Refractory: dapsone, antimalarials, mycophenolate, azathioprine

EM major (severe mucosal)

  • Ophthalmology, urology/gynecology consultation as needed
  • Hospitalization for dysphagia, dehydration, or severe pain
  • Short course systemic corticosteroids (controversial) — prednisone 0.5-1 mg/kg/day tapered over 1-3 weeks for severe cases
  • Treat underlying infection aggressively

Second-line / adjunct

  • Cyclosporine, dapsone, hydroxychloroquine, IVIG for recurrent steroid-dependent or refractory cases
  • Avoid prophylactic systemic steroids — efficacy unproven and may prolong recovery in some studies

Complications

  • Mucosal scarring (rare in EM, more common in SJS/TEN)
  • Secondary bacterial infection of erosions
  • Conjunctival inflammation, rare ocular sequelae
  • Recurrent episodes affecting quality of life
  • Misdiagnosis as SJS/TEN leading to unnecessary aggressive therapy

PANCE pearls

  • True target lesions have THREE distinct zones; SJS/TEN lesions are typically atypical with two zones or flat dusky macules.
  • EM is acral and centripetal; SJS/TEN is truncal and centrifugal.
  • Recurrent EM is HSV-driven in the vast majority — long-term suppressive antivirals are highly effective.
  • Mycoplasma-induced rash and mucositis (MIRM) in children was previously classified as EM but is now considered a distinct entity with mucositis predominating over skin lesions.
  • Drugs more often cause SJS/TEN than true EM — re-examine the diagnosis if onset followed a new drug.

References

  • AAD 2019 — Clinical Features and Management of Erythema Multiforme (AAD review series)
  • Trayes 2019 — Erythema Multiforme: Recognition and Management (Trayes et al., Am Fam Physician 2019)
  • Sokumbi 2012 — Clinical Features, Diagnosis, and Treatment of Erythema Multiforme (Sokumbi and Wetter, Int J Dermatol 2012)

Practice Dermatology questions on FirstPassPA

Turn this outline into retention. 6,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.

Answer the 2 free questions above → Get today's free question →

Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.